Market Herald logo


Be the first with the news that moves the market
  • EXMceuticals (EXM) has appointed Michael Kinley as its Chief Financial Officer
  • Mr. Kinley is a Chartered Professional Accountant with 30 years of experience in senior roles with public companies
  • The appointment of Mr. Kinley comes after sweeping changes to EXMceuticals’ upper management
  • EXMceuticals also announced the granting of 466,931 stock options to an unnamed director
  • Shares in the company are currently up 5% to $0.42, with a market cap of $16.66 million

Cannabis cultivator and producer, EXMceuticals (EXM) has announced the appointment of Michael Kinley as the company’s new Chief Financial Officer.

A former partner with KPMG, Mr. Kinley is a Chartered Professional Accountant and has been President of Winslow Associates Management & Communications – a private consulting firm – since 1993.

Over the past 30 years, Mr. Kinley has also served as an officer and director of several public companies.

“Mr. Kinley brings with him extensive experience in the regulatory market and has a long history of leading junior companies. Mr. Kinley is a great addition to the EXM management team, and he frankly impressed us from our first conversation,” said EXMceuticals CEO and Chairman, Jonathan Summers.

“I am pleased to welcome Michael as permanent CFO and I am looking forward to working with him on executing our strategy in becoming a leading low-cost producer of high-quality cannabis and hemp ingredients for the European and North American markets.”

Mr. Kinley’s appointment comes after a host of announcements revealing changes to EXMceutical’s upper management.

In the last few weeks, the company has named Paulo Martins as its Chief Executive Officer for its operations in Portugal, and appointed both Nick Davis and Prof. Dr. Eurico Castro Alves to its Advisory Board.

In addition to Mr. Kinley’s appointment, EXMceuticals also said that it had granted stock options to an unnamed director to purchase a total of 466,931 common shares at a price of $2.00, exercisable for a period of ten years.

Shares in the company are currently up 5% to $0.42, with a market cap of $16.66 million.

More From The Market Herald

" BioHarvest (CSE:BHSC) predicts 2022 revenue to grow up to 3.5 times

BioHarvest Sciences Inc. (BHSC) expects strong revenue growth to continue in 2022 due to a successful over-delivery of projected revenue targets from last year.

" Icanic Brands (CSE:ICAN) agrees to acquire cannabis extraction company

Icanic Brands Company (ICAN) has signed a definitive agreement to acquire 100 per cent of LEEF Holdings Inc.
Tilray - Denise Faltischek, Head of International and Chief Strategy Officer.

" Tilray (TSX:TLRY) expands Australian medical cannabis offering

Tilray (TLRY) has expanded its medical cannabis product suite in Australia.

" Craftport Cannabis (CSE:CFT) announces $3M private placement

Craftport Cannabis (CFT) has announced a non-brokered private placement for gross proceeds of $3 million.